Side-by-side comparison of AI visibility scores, market position, and capabilities
Amazon-owned audiobook platform with 750K+ title catalog; monthly credit subscription with Originals competing with Spotify and Libro.fm for dominance in the growing audiobook market.
Audible is Amazon's dominant audiobook and podcast platform providing digital audiobooks, audio dramas, and original audio content through a monthly subscription that gives subscribers credits to purchase audiobooks from its catalog of 750,000+ titles — making it the world's largest audiobook platform and a major force in the publishing industry. Founded in 1995 by Don Katz in Wayne, New Jersey and acquired by Amazon in 2008 for approximately $300 million, Audible generates estimated revenue of $1.5+ billion annually and is now deeply integrated into Amazon's broader reading and content ecosystem.\n\nAudible's subscription model (Audible Premium Plus at $14.95/month) provides one audiobook credit per month (redeemable for any title regardless of price), plus access to Audible Originals and a growing selection of Plus Catalog titles included with subscription. The app works offline, enables variable playback speed (many users listen at 1.5-2x), and integrates with Amazon Echo devices through Alexa. Audible Studios produces exclusive original audio content including adaptations of bestselling books and celebrity-narrated titles.\n\nIn 2025, Audible competes with Spotify (which has made major investments in audiobooks through its subscription), Libro.fm (independent bookstore-affiliated), Google Play Books, and Apple Books for audiobook market share. Audible's dominant catalog position and Amazon integration provide significant advantages, but Spotify's entrance into audiobooks with Spotify Premium subscribers getting a limited number of monthly audiobook hours has created new competitive pressure. Audible's 2025 strategy focuses on expanding its Originals catalog (which drives differentiated subscription value), deepening integration with Kindle for read-along experiences, and growing international markets particularly in Germany, UK, and France.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.